USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Q THERAPEUTICS, INC.
Address:
Q THERAPEUTICS, INC.
421 WAKARA WAY, STE 201
SALT LAKE CITY, UT 84108
Phone:
(801) 581-0400
URL:
N/A
EIN:
460490491
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $294,914.00 3

Award List:

NUCLEAR/CYTOPLASMIC RATIO-EFFECTS ON EMBRYO DEVELOPMENT

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$49,996.00
Agency:
HHS
Principal Investigator:
Frank l. barnes , PRINCIPAL INVESTIGATOR
Abstract:
N/a

A novel technology for protein delivery to the CNS

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$126,563.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term objective of this research is to develop a cell-based system for delivering therapeutic gene products to brain and spinal cord. Several candidate protein pharmaceuticals exist whose use for treatment of genetic or other CNS disorders is severely… More

Development of Astrocyte-Restricted Precursors for Cell Therapy and Drug Screenin

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$118,355.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term objective of this research is to develop a cell therapy for the treatment of neurological disorders that are due to dysfunctional astrocytes. Current approaches to cure or manage these diseases by small mo lecule drugs are limited due to the… More